ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Spread the love

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET

Company Participants

Al Kildani – Corporate Participant
Catherine E. Owen Adams – CEO & Director
Elizabeth H. Z. Thompson – Executive VP and Head of Research & Development
Mark C. Schneyer – Executive VP & CFO
Thomas Andrew Garner – Executive VP & Chief Commercial Officer

Conference Call Participants

Leo Gene Watson – Mizuho Securities USA LLC, Research Division
Malcolm Hoffman – BMO Capital Markets Equity Research
Marc Harold Goodman – Leerink Partners LLC, Research Division
Michael H. Riad – Morgan Stanley, Research Division
Ritu Subhalaksmi Baral – TD Cowen, Research Division
Salveen Jaswal Richter – Goldman Sachs Group, Inc., Research Division
Tazeen Ahmad – BofA Securities, Research Division
Tessa Thomas Romero – JPMorgan Chase & Co, Research Division
Yatin Suneja – Guggenheim Securities, LLC, Research Division
Ami Fadia – Needham & Company, LLC, Research Division
Ashwani Verma – UBS Investment Bank, Research Division
Brian Corey Abrahams – RBC Capital Markets, Research Division
David Timothy Hoang – Deutsche Bank AG, Research Division
Jason Nicholas Butler – Citizens JMP Securities, LLC, Research Division
Julian Hung – Stifel Nicolaus Canada Inc., Research Division

Operator

Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Gerald, and I’ll be your host for today. I would now like to turn the conference over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at ACADIA. Please proceed.

Al Kildani

Thank you. Good afternoon, and thank you for joining us on today’s call to discuss ACADIA’s second quarter 2025 financial results. Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks; followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, DAYBUE and NUPLAZID. Also joining